ZOVIRAX
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Oct 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZOVIRAX (acyclovir) is an injectable small-molecule antiviral that inhibits α-herpesvirus DNA polymerase to treat herpes labialis. The drug has been a foundational herpesvirus therapy since 1982, approved via NDA by GSK. It works by blocking viral DNA replication in infected cells.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); GSK brand team likely managing end-of-life strategy and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and LOE-approaching status, ZOVIRAX offers limited career growth opportunities at GSK. Roles on this product focus on cost management, generic transition, and market exit planning rather than expansion or innovation.
Brand ManagerProduct Manager
Worked on ZOVIRAX at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.